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Abstract
Renal replacement therapies (RRTs) represent a
cornerstone in the management of severe acute
kidney injury. This area of intensive care and
nephrology has undergone significant improvement
and evolution in recent years. Continuous RRTs have
been a major focus of new technological and
treatment strategies. RRT is being used increasingly in
the intensive care unit, not only for renal indications
but also for other organ-supportive strategies. Several
aspects related to RRT are now well established, but
others remain controversial. In this review, we review
the available RRT modalities, covering technical and
clinical aspects. We discuss several controversial issues,
provide some practical recommendations, and where
possible suggest a research agenda for the future.
Introduction
Acute kidney injury (AKI) is common in critically ill
patients and is associated with high mortality and
morbidity [1]. In patients with severe AKI, renal
replacement therapy (RRT) represents a cornerstone of
treatment. Although much progress has been made in this
area, many questions remain unanswered [2].
The aim of this review is to present a multidimensional
update of RRT in AKI with a focus on mechanisms and
modalities, anticoagulation, and extended indications.
The topics of plasmapheresis and RRT during extra-
corporeal membrane oxygenation will not be covered
in this review.
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Principles of modern renal replacement therapy
Current RRT machines present multiple integrated
components, including four- to five-roller pumps,
three to four integrated scales, four to five pressure
pods, reliable air detection, integrated pumps for heparin
or citrate/calcium infusion, ultrafiltration, and various
safety alarms. Considerable effort has gone into providing a
user-friendly interface, limited error ranges, and possibility
for data download/integration to electronic health records.
New machines are often more a platform for multiple
techniques than a simple dialysis monitor.
Extracorporeal circuit
Extracorporeal therapies are now exclusively delivered
through double-lumen venous catheters. With few
exceptions, blood flow is ensured by a peristaltic roller
pump. Circuit pressures are constantly monitored in
every part of the circuit (pre-pump or access pressure,
pre-filter, effluent). Furthermore, pressure drop and
transmembrane pressures are calculated by the machine
in order to monitor the filter clotting process. The most
important aspect of filter patency is the process of concen-
tration polarization, which is the accumulation of particles
(mostly of protein nature) in the inner part of the hollow
fiber that leads to a progressive decrease in membrane
permeability and performance [3,4]. Possible solutions to
reduce filter clotting and deterioration in membrane perme-
ability are maximization of the blood flow rate (Qb)
and optimization of the ultrafiltration-to-blood flow
ratio - filtration fraction (FF) percentage - for post-dilution.
Today, Qb values of greater than 200 mL/minute are easily
achievable, and FF percentages of less than 20% are advised.
Other strategies, such as changes in the structure of the
fiber (inner diameter) and in filter geometry (length and
number of fibers), are manufacturer-dependent.
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Vascular access
Vascular access is a particularly important determinant
of the quality of RRT [5]. A large trial found that the
jugular and femoral sites were equivalent in terms of
infectious complications; however, jugular vein insertion
may be preferable in obese patients [6]. Insertion in the
left jugular vein has been associated with greater rates of
catheter dysfunction compared with the right jugular
vein or femoral veins [7]. Deeper insertion of jugular
catheters with positioning in the right atrium has an
advantage in terms of filter life and may be associated
with better performance [8]. The subclavian veins should
be avoided when possible as there is a risk of thrombosis
which, in the event of non-recovery, can jeopardize
arteriovenous fistula placement for chronic dialysis.
The catheter diameter ideally should be about one
third of the vein diameter to minimize vessel throm-
bosis. Ultrasound-guided positioning of catheters is
recommended [2].
Pre- or post-dilution
Hemofiltration (HF) is a process that parallels what
occurs in the human glomerulus [9]. The tubular function
is mimicked by fluid reinfusion to compensate, in total or
in part, for the amount of filtered fluid. Reinfusion
guarantees restoration of hematocrit to previous values
and ensures solute dilution in the blood. Reinfusion can
be performed before (pre-dilution) or after (post-dilution)
the filter. Pre-dilution HF is less efficient because the
filtrate contains fewer solutes since the blood will have
been diluted before entering the filter. Nevertheless, the
lower hemoconcentration inside the filter reduces the risk
of clotting. Post-dilution is the best way to estimate
creatinine/urea clearance in HF because clearance equals
effluent rate. In post-dilution HF, the phenomenon of
concentration polarization may induce membrane fouling
and filter clotting. If pre-dilution HF is selected, protein
layer deposition is reduced, but the efficiency of the
treatment is reduced and the dose is not linearly pro-
portional to the effluent rate [9]. Clearance is calculated
by the effluent rate corrected for the dilution factor. No
clinical study has definitively addressed when pre- or
post-dilution HF should be used, so this decision is largely
a matter of local experience and preference.
Ultrafiltration
Fluid overload is associated with adverse outcomes in
critical illness [10] and often represents a primary
indication for RRT. Capillary leak and hypoalbuminemia
predispose patients to the accumulation of interstitial
edema and slow intravascular refilling. After initial resusci-
tation, it is crucial to avoid unnecessary fluid accumulation
to limit later requirements for fluid removal. Patients
should be actively assessed for the presence of fluid
overload, and the rate and final target of fluid removal
must be carefully considered and frequently reassessed,
whichever method is used to achieve this. Setting the rate
of removal requires consideration of the severity of
complications of fluid overload, anticipated fluid intake,
expected rate of vascular refilling, and cardiovascular
tolerance to transient reduction in intravascular volume
due to ultrafiltration. Techniques such as bioimpedance
analysis and relative blood volume monitoring may assist
in setting targets for total volume and rate of fluid
removal, although these techniques have not been widely
applied in the intensive care unit (ICU) [11,12]. Of note,
although many tools can be used to predict the response
to fluid administration (such as pulse pressure variations
or passive leg-raising), there are no good indicators to
predict tolerance to fluid removal. A fluid removal trial
(reverse fluid challenge [13]) is therefore often the only
option while assessing cardiovascular tolerance with the
available hemodynamic tools.
Timing, mode, and dose of renal replacement
therapy
When to start renal replacement therapy
The timing of initiation of RRT remains controversial. It
is clear that derangements of, for example, potassium,
acid–base balance, pronounced azotemia, and fluid
overload (called the ‘conventional criteria’ [14] for initiating
RRT) need correction. However, clinicians have difficulty
estimating the likelihood of recovery from evolving AKI
and this complicates the decision to start RRT. Renal
biomarkers may be helpful in determining which patients
will recover renal function prior to [15] or after [16] the
initiation of RRT. Also, an isovolumic ‘furosemide stress
test’ may help predict which patients will progress to more
severe AKI [17].
The decision when to start RRT is not merely academic
but may impact on outcomes. Although it has been
suggested that early application of RRT in patients with
severe sepsis, irrespective of the presence of renal failure,
might be beneficial (for example, by modifying the
plasma concentrations of inflammatory mediators [18]),
early ‘classic dose’ continuous veno-venous hemofiltration
(CVVH) did not limit further organ damage and even
prolonged the need for organ support [19]. Nevertheless,
although early initiation of RRT is not clearly associated
with benefit, avoiding or delaying RRT is associated with
higher mortality and increased hospital/ICU lengths of
stay [20-22]. Based on these data, no clear guidance as to
when to start RRT can currently be given. In addition, the
terms ‘early’ and ‘late’ RRT are subjective and there is no
reference definition.
Interestingly, fluid overload may be a major outcome
determinant for critically ill patients with AKI at
continuous renal replacement therapy (CRRT) start [23];
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it is possible that starting ultrafiltration when a lower
degree of fluid accumulation has been reached and
targeting a negative fluid balance in the first treatment
hours may improve outcome. However, the only available
data so far come from retrospective studies or post hoc
analyses [23], so that it is impossible to recommend a
priori at what level of fluid gain RRT should be started or
the net ultrafiltration rate that should be prescribed; these
factors should be tailored according to individual patient
requirements.
When to stop renal replacement therapy
There is an even greater paucity of data on when to stop
CRRT. RRT can be stopped when there is sufficient
improvement in renal function, but how this can be
evaluated while the patient is still receiving RRT remains
unclear. Current practice suggests measuring urine
output and serum creatinine levels while on a constant
dose of CRRT and calculating the endogenous creatinine
clearance by using both the urine and serum concentra-
tions of creatinine. Decisions to delay or stop the next
RRT session may be easier for intermittent treatments.
Observational studies have shown that the most significant
predictor of successful termination of CRRT is urine output
[24]. A urine output of more than 400 mL/day is a reason-
able cutoff value, resulting in correct classification in 79%
of patients [25]. Not surprisingly, this predictive ability can
be negatively influenced by the use of diuretics. However,
the furosemide-induced response in patients without
immediate recovery of renal function within 24 hours after
cessation of CRRT can help predict eventual renal recovery
[26]. The precise level of endogenous creatinine clearance
needed to allow discontinuation of renal support has not
been established but is assumed to be between 15 and
20 mL/minute. The need for RRT reinstitution is associated
with increased mortality [25], likely reflecting a
marker of disease severity rather than indicating that
too early discontinuation is harmful. Administration
of furosemide after termination of RRT increases
urinary volume and sodium excretion but does not
shorten the duration of renal failure [27]. To date, no
study has used a marker other than creatinine as a
measure of renal function. The fact that serum neutrophil
gelatinase-associated lipocalin (NGAL) concentrations
decreased when serum creatinine levels started to increase
following cardiac surgery [28] and that the plasma
clearance of NGAL is only 5 mL/minute during CRRT
[29] suggests that biomarkers that reflect renal damage or
function and that are not cleared by the CRRT may be
useful to detect improvements in renal function while on
CRRT. In the Acute Renal Failure Trial Network
(ATN) study [30], creatinine clearance was assessed
(using a 6-hour urine collection) when urine output
exceeded 30 mL/hour or a decrease in creatinine level
occurred while on CRRT. Renal support was discontinued
when the measured creatinine clearance exceeded
20 mL/minute and was left to the discretion of providers
when in the range of 12 to 20 mL/minute [30]. This
approach currently represents the most accurate means of
estimating when to end RRT.
Continuous versus intermittent techniques
Intermittent hemodialysis (IHD) was originally conceived
as a treatment for acute renal failure, and CRRT was
introduced as an alternative when IHD was contraindicated.
Subsequently, CRRT has become a routine therapy for AKI
in many countries but may not be available in some
resource-limited settings. Intermittent therapy has
advantages in facilitating rehabilitation and other aspects
of therapy for some patients. However, when applied
correctly, both continuous and intermittent modalities
can achieve a satisfactory degree of metabolic control in
most patients, and randomized controlled trials (RCTs)
and meta-analyses have not shown a difference between
modalities in terms of patient survival rates. The reasons
for this lack of evidence may still lie in the selection of
patients for the study populations, with many of the most
severely ill patients excluded. Importantly, a systematic
analysis of RRT modality and its effect on renal recovery
from dialysis dependence in critically ill patients found
that CRRT was associated with a higher rate of renal
recovery compared with IHD [31], suggesting that the use
of CRRT may be more cost-effective than previously
thought [32,33], especially as the real cost of conventional
IHD is significantly higher than previously estimated [34].
However, these results were limited to observational
studies, and no difference was found when the analysis
was restricted to randomized trials. There is a broad
consensus that, compared with standard IHD, CRRT may
be the optimal treatment for hemodynamically unstable
patients [2], and IHD may be a more suitable option when
patients have left or are soon to leave the ICU.
Hybrid therapies
Various ‘hybrid therapies’ [35,36] or ‘prolonged (daily)
intermittent RRTs’ have been proposed as intermediate
forms of therapy between continuous and intermittent.
These techniques use various approaches, including
sustained low-efficiency (daily) dialysis (SLE(D)D) and
extended daily dialysis. In these techniques, conventional
IHD equipment is adapted to provide longer session
durations with lower flows and efficiency [35-37].
Several trials have indicated that the degree of
hemodynamic stability with SLED and CRRT is quite
similar [36-38]. One small trial found no difference
between SLED and CVVH in terms of mortality (the
primary endpoint), but SLED was associated with
shorter lengths of stay and duration of mechanical
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ventilation (secondary endpoints) [39]. Possible further
advantages of SLED may be more rapid mobilization of
patients, which may result in shorter ICU stays and more
rapid convalescence. Controversy exists regarding the
definition of SLED as reported session times vary from as
short as 6 hours every other day, thus resembling standard
IHD, to more than 12 hours every day, thus approaching
CRRT. An RCT investigating intensified SLED aimed at
blood urea nitrogen (BUN) levels of less than 45 mg/dL
did not show improved outcome compared with daily
SLED achieving an average BUN of 60 to 75 mg/dL [40].
Another potential problem with SLED relates to difficulty
in optimizing doses of antibiotics. There is an increased
risk of antibiotic underdosage during the second half of
the SLED session. This may be particularly relevant for
patients infected with multiresistant strains. Despite avail-
ability of these approaches, clinical use so far has been
limited to only a relatively small number of centers.
Dose of renal replacement therapy
The dose of RRT is equivalent to the normalized dose of
therapy delivered to the patient. In the past, RRT was
largely under-dosed in critically ill patients. However,
since the milestone trial by the group of Vicenza in 2000
[41], a dose of 35 mL/kg per hour has been widely used,
with a trend to increased doses in patients with sepsis [42].
Two large multicenter RCTs, the Randomized Evaluation
of Normal versus Augmented Level of Renal Replacement
(RENAL) and ATN studies [30,43], showed that increased
intensity of RRT was not associated with improved patient
outcomes. As a consequence, the recommended ‘normal
dose’ is now in the range of 20 to 30 mL/kg per hour for
continuous therapies. This observation does not mean that
individual patients may not benefit from higher doses when
hypercatabolic states or sepsis is present.
In patients who had higher day 1 concentrations of
plasma inflammatory mediators, intensive RRT was
associated with reduced levels over the first week but no
significant effect on renal recovery or mortality [44].
However, numerous studies have shown that persistently
elevated concentrations of inflammatory markers are
associated with RRT dependence and death [45,46]. These
observations suggest that a personalized approach, mapping
RRT intensity to biomarker levels, could be a more effective
option. These effects, however, may be too small to trans-
late into clinical benefit. Better technology is probably
needed, possibly coupling RRT intensity with monitoring of
different biomarkers over time (Figure 1).
Potential complications
Metabolic complications
The increased solute clearance achieved by CRRT
may cause unwanted losses of amino acids, vitamins,
catecholamines, and other compounds [47]. Severe
hypophosphatemia (<1.0 mg/dL; <0.32 mmol/L) occurs in
about half of ICU patients [48], and CRRT can contribute
to this deficiency [49], especially when high-intensity
treatment is prescribed. Hypophosphatemia is associated
with respiratory and cardiac depression and immune
dysfunction [50]. This condition should be prevented or
adequately treated with supplementation, especially in
CRRT patients. Phosphate-containing CRRT replacement
fluids which protect against hypophosphatemia are now
available [51]. Hypomagnesemia can also occur during
CRRT as the replacement fluid also lacks magnesium.
Anticoagulation
Sufficient anticoagulation, without excessive risk of
bleeding, is generally required to maintain filter and
circuit patency in RRT. Although the precise definition
of adequate filter patency is a matter of debate, most
available membranes will have significant protein
concentration polarization and pore fouling after 20 to
24 hours. Point-of-care (POC) techniques of coagulation -
for example, rotational thromboelastometry and throm-
boelastography - are increasingly being used for rapid spe-
cific testing of hemostatic function in critically ill patients
and during anesthesia with important clinical benefits [52].
Nevertheless, very few studies have addressed the utility of
POC techniques in critically ill patients during CRRT [53].
Because standard laboratory tests of blood coagulation
may be of limited value to detect the changes during RRT,
we anticipate that POC coagulation testing will be used
more frequently during RRT, especially in septic patients,
in whom early clotting of the cartridge may occur.
Heparin, heparinoids, and thrombin inhibitors
Unfractionated heparin (UFH) is still the most widely
used anticoagulant [54]. The major advantages of UFH
are low costs, ease of administration, simple monitoring,
and reversibility with protamine. The half-life of UFH is
about 90 minutes, increasing to up to 3 hours in renal
insufficiency because of accumulation of smaller fragments
[55]. The activated partial thromboplastin time is still the
best option for monitoring but may not be a reliable
predictor of bleeding [56]; levels of greater than 45 to
50 seconds have been associated with an increased
risk of bleeding [57]. At this low level of anticoagulation,
the activated clotting time is relatively insensitive. A
possible scheme for UFH consists of a bolus of 30 IU/kg
followed by an initial rate of 5 to 10 IU/kg per hour in
patients with normal coagulation. In addition to bleeding,
other side effects of UFH include the development of
heparin-induced thrombocytopenia (HIT) and effects on
serum lipids; efficacy is also dependent on antithrombin
levels, and substitution may be needed in patients with
severe sepsis and heparin resistance [58].
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Low-molecular-weight heparins (LMWHs) have several
advantages over UFH, including a lower incidence of
HIT, less affinity for antithrombin, less platelet (and
polymorphonuclear cell) activation, less inactivation by
platelet factor-4, greater and more consistent bioavailability,
and no metabolic side effects [55]. However, LMWHs are
eliminated by CRRT. Although some studies have
used fixed doses of an LMWH, continuous intravenous
administration of LMWH adjusted to achieve systemic
anti-Factor Xa levels of 0.25 to 0.35 U/mL may be the
safer option, resulting in improved filter survival as
compared with UFH [59]. However, anti-Xa levels may
not be a reliable predictor of bleeding [60]. Whenever
HIT is diagnosed or suspected, all heparins should be dis-
continued and replaced by an alternative anticoagulant
[61], such as danaparoid or a direct thrombin inhibitor
(for example, bivalirudin or argatroban) (Table 1).
Regional citrate anticoagulation
The complications associated with systemic heparin admin-
istration stimulated interest in regional anticoagulation
techniques and especially regional citrate anticoagulation
(RCA) [62-64]. Sodium citrate is infused before the patient’s
blood enters the CRRT circuit, and forms a complex with
ionized calcium, removing this key component from the
coagulation pathways. Extracorporeal calcium concentra-
tions of less than 0.35 mmol/L are usually sufficient
for regional anticoagulation, requiring citrate doses of
approximately 4 to 6 mmol/L blood. Most of the calcium
citrate complexes quickly pass the filter membrane and
are lost in the effluent volume. The remaining calcium
citrate enters the systemic circulation and is metabolized
in the liver, muscle, and kidney, producing three molecules
of bicarbonate for each molecule of citrate. Citrate,
therefore, can have general metabolic consequences;
for example, in the presence of severe liver failure,
citrate accumulation may occur and is best detected
by the total calcium-to-ionized calcium ratio - a ratio of
more than 2.5 indicates citrate accumulation syndrome
and treatment must be stopped. Additional calcium infu-
sions compensate for extracorporeal losses in the circuit,
maintaining the patient’s normal calcium levels [63].
Compared with systemic heparin, RCA has been associ-
ated with less bleeding, increased filter lifespan, and reduced
transfusion rates and need for antithrombin III/platelet
supplementation [65-67]. RCA has also been shown to have
potential anti-inflammatory effects, including reduced
degranulation of polymorphonuclear cells and increased
formation of platelet-leukocyte complexes, oxidative stress,
and interleukin-1-beta release [68-70]. The impact of RCA
on outcome has not been clearly demonstrated [65,66,71],
Although KDIGO (Kidney Disease: Improving Global
Outcomes) guidelines suggest that citrate be used for all
patients without contraindications and heparin for other
Figure 1 The ‘ideal’ future renal replacement technology. The ‘ideal’ future renal replacement technology will couple renal replacement
therapy intensity (treatment delivery) with different bio-feedback systems to tailor dose and ultrafiltration rate to the complex needs of the
individual critically ill patient. EKG, electrocardiogram; Tx, treatment.
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patients [72], some prefer to keep heparin as a first-choice
treatment, especially for units using RRT less frequently,
but to replace it with citrate in patients with a high risk of
bleeding. As technological advances facilitate citrate use,
we anticipate increased use.
Antibiotic dosing during renal replacement therapy
Early and adequate antibiotic therapy is crucial in critically
ill patients with signs and symptoms of infection. AKI
alters antibiotic elimination, leading to drug accumulation
[73], and the use of CRRT may further modify antibiotic
pharmacokinetics [74,75]. However, current recommenda-
tions on antibiotic dosing during CRRT are based on
studies that included a limited number of patients, that
had varying inclusion/exclusion criteria, and that included
patients who received different types of RRT [74,76,77].
Effluent flow rate was the most reliable predictor of anti-
biotic clearance in critically ill patients, and higher dosing
regimens may be required in critically ill patients receiving
RRT [78,79], in particular for poorly susceptible strains.
Nevertheless, this strategy may also be associated with
very high drug levels in the late phase of therapy, with the
potential development of drug-related side effects [80].
When possible, therefore, antibiotic concentrations should
be measured in patients undergoing CRRT and dosing
schedules adapted to the individual patient.
Renal replacement therapy as an adjunct in sepsis
Cytokines and other inflammatory mediators contribute
to the pathogenesis of septic shock and sepsis-associated
AKI [81]. However, although CRRT removes inflammatory
cytokines and partially modulates plasma cytokines,
outcomes do not seem to be affected regardless of
the dose applied [19,82-84]. These findings may be due to
the timing of implementation and patient selection.
Moreover, whereas studies have found that inflammatory
mediators vary widely in patients with sepsis [85],
blood purification studies have generally not measured
inflammation as part of the inclusion criteria.
Standard filtration or dialysis membranes - even when
used with high-volume HF - have demonstrated only
limited effectiveness in removing cytokines, the vast
majority of which are water-soluble and of mid-range
molecular weight (5 to 51 kDa) [84]. This is most likely
attributable to the limited pore size of standard blood
purification membranes. Recently, high cutoff (HCO)
membranes with moderately larger pore sizes have been
developed and found to have greater cytokine removal
capacity compared with standard high-flux membranes
in ex vivo experiments, animal experiments, and prelimin-
ary clinical studies [86,87]. Moreover, HCO membranes
were associated with beneficial effects on immune cell func-
tion and increased survival in animal models of sepsis [88].
This technology may represent a valuable tool to attenuate
the inflammatory response in patients with septic shock.
Further studies of HCO RRT in the treatment of patients
with septic shock appear warranted.
Adsorption
It has been suggested that by separating the plasma so
that cells do not come into contact with the sorbent, a
system would need to be less hemocompatible but could be
more effective. Coupled plasma filtration and adsorption
(CPFA) separates plasma from blood by means of a plasma
filter. The plasma is then passed through a synthetic resin
cartridge for adsorption and returned to the blood. Unlike
standard RRT, adsorption is very effective in removing large
solutes. Once the blood has been reconstituted, a second
blood filter can be used to remove excess fluid and
small-molecular-weight toxins. CPFA and CRRT then
can operate in series. A pilot clinical study using
CPFA in sepsis demonstrated a marked resolution of
immunoparalysis with function of circulating leukocytes
restored to normal [89]. A recent study suggested that
treating high volumes of plasma may be an important
objective of CPFA, but this is difficult to achieve [90]. An
RCT of high-dose CPFA in patients with septic shock
is ongoing in several Italian centers (ClinicalTrials.gov
identifier: NCT01639664).
Polymyxin B hemoperfusion
Polymyxin B hemoperfusion has been shown to decrease
macrophage and monocyte activity and to inactivate
circulating pro-apoptotic factors potentially involved in
the pathogenic mechanisms of sepsis-associated AKI
[91,92]. A systematic review of available clinical studies sug-
gested beneficial effects on arterial pressure, gas exchange,
and even mortality [93]. In a recent meta-analysis [94],
RRT, and especially hemoperfusion, was associated
with improved survival in patients with sepsis. However,
many of the studies were limited by suboptimal methodo-
logical quality. In EUPHAS (Early Use of Polymyxin B
Table 1 Alternative anticoagulation in heparin-induced thrombocytopenia [115-119]
Danaparoid Bivalirudin Argatroban
Dosing 3,500 IU bolus, followed by 100 units/hour or
140 IU/hour without bolus
0.03-0.2 mg/kg per hour Bolus 100 μg/kg followed by 0.1-0.5 μg/kg
per minute
Monitoring Anti-Xa activity 0.25-0.35 IU/mL (0.5-1.0 IU/mLa) Target aPTT ratio 1.5 (−2.5a) Target aPTT ratio 1.5 (−3.0a)
Main adverse events Cross-reactivity with HIT-ab No data Anemia; accumulation in liver failure
aIf systemic anticoagulation is required. aPTT, activated partial thromboplastin time; HIT-ab, heparin-incuded thrombocytopenia antibody.
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Hemoperfusion in Abdominal Sepsis), a prospective
multicenter RCT in 64 patients with severe sepsis or
septic shock who underwent emergency surgery for
intra-abdominal infection, addition of polymyxin B
hemoperfusion to standard therapy was associated with
improved blood pressure, reduced organ failure, and
possibly improved survival [95]. Final results from
the ABDO-MIX study (ClinicalTrials.gov identifier:
NCT01222663), a randomized multicenter study in
patients with septic shock undergoing surgical treatment
for peritonitis, have not yet been published, but there
was no improvement in survival with polymyxin B
hemoperfusion. The EUPHRATES trial (ClinicalTrials.
gov identifier: NCT01046669) is ongoing in North
America and hopefully will definitively evaluate the
safety and efficacy of polymyxin B hemoperfusion in
patients with septic shock.
Renal replacement therapy in other conditions
Cardiac failure and cardiorenal syndromes
Patients with cardiac failure have reduced cardiac output
and arterial underfilling but also venous congestion.
Both of these aspects may cause AKI by reducing renal
perfusion pressure [96,97]. Mechanical ultrafiltration may
be useful to resolve fluid overload by achieving better
sodium removal per unit volume than diuretic therapy,
thus resulting in better improvement of cardiovascular
function. In the UNLOAD study [98], ultrafiltration
compared with diuretics in patients with cardiac failure
and impaired renal function resulted in lower rates
of re-hospitalization, but the subsequent CARRESS
(Effectiveness of Ultrafiltration in Treating People With
Acute Decompensated Heart Failure and Cardiorenal
Syndrome) study [99], in a similar population, was
discontinued early with no evidence of benefit from
ultrafiltration. However, in the CARRESS study,
ultrafiltration was applied without clear evidence of
diuretic resistance and fluid removal was set at a
fixed rate for all patients and without the same level
of hemodynamic support allowed in the pharmacological
arm. Finally, in a case series of 63 chronic heart failure
patients with diuretic-resistant fluid overload, treatment
with slow continuous ultrafiltration was associated with
an improvement in central pressures and cardiac index
after 48 hours of treatment [100]. Outcomes were
favorable in patients who did not require transition to
RRT for solute clearance; however, only 8 of 37 who
received RRT survived with recovered renal function.
Thus, diuretic resistance and the need for RRT may
be markers of the severity of chronic disease and of
poor outcome where treatment options may be limited.
Furthermore, HF, but not ultrafiltration, may allow sodium
and water removal to be dissociated, with specific
homeostatic benefits in acute cardiorenal syndromes.
Respiratory failure
Respiratory failure is frequently associated with impaired
renal function. Reduced cardiac output because of
increased thoracic pressure results in activation of
volume regulation characterized by sodium and water
retention as well as reduced renal blood flow [101].
Fluid retention results in interstitial edema, which
compromises pulmonary function by increasing extra-
vascular lung water. The resulting increase in central
venous pressure may play a significant role in reducing
glomerular filtration rate [96]. Injurious mechanical
ventilation is also characterized by a systemic release
of cytokines, which is an additional risk factor for
AKI [102]. AKI in turn results in decreased cytokine
clearance and increased systemic release of inflammatory
markers, resulting in increased alveolar fluid and a
pulmonary inflammatory reaction, even in previously
healthy lung [103]. Overall, this vicious circle tends to
terminate in acute respiratory distress syndrome (ARDS)
and AKI. Thus, applying protective ventilation using tidal
volumes of around 6 mL/kg [104] may also be considered
kidney-protective ventilation. In the presence of massive
fluid overload and ARDS, CRRT may be considered to
reduce extravascular lung water and allow less invasive
ventilation. Combinations of RRT with extracorporeal
CO2 removal techniques may help to re-establish
acid–base homeostasis and reduce vasopressor demands
as well as ventilation pressures. Though not as effective as
extracorporeal membrane oxygenation, extracorporeal
CO2 removal in series with CRRT may contribute to fur-
ther reduce tidal volumes (ultraprotective ventilation) or
even help to avoid intubation [105,106].
Acute brain injury
AKI occurs in 8% to 23% of patients with acute brain
injury and is an independent predictor of poor outcome in
these patients [107,108]. AKI is associated with several
complex pathological pathways, including sodium im-
balance, alteration of nitric oxide synthase expression,
and inhibition of gamma-aminobutyric acid neuro-
transmission, which can all result in brain injury; AKI
is also associated with increased brain inflammation
and increased blood–brain barrier (BBB) permeability
[109]. Interestingly, the increased urea and solute
levels in the blood also result in an intra-cerebral
shift of these molecules as well as increased cerebral
water content [110]; this process is more marked in
patients with acute brain injury because of the disrupted
BBB and altered aquaporin metabolism. Thus, when RRT
is initiated in patients with acute brain injury, the decrease
in serum osmolarity can create an osmotic gradient across
the BBB, which will be compensated by a shift of water
into the brain compartment, thus contributing to increase
intracranial pressure (ICP) [111]. Another potentially
Ronco et al. Critical Care  (2015) 19:146 Page 7 of 11
adverse cerebral event associated with RRT in such
patients is arterial hypotension, which could result in
brain hypoperfusion. The use of bicarbonate buffers
in RRT can also increase CO2 production and thus
brain CO2 partial pressure, with cerebral vasodilation
and risk of increased ICP.
CRRT should be the first option in these patients because
it is associated with less increase in ICP compared with
intermittent therapies [111]. CRRT is also associated with
better maintenance of cerebral blood flow autoregulation
after traumatic brain injury [112]. Because of the risk of
cerebral hemorrhage with systemic heparin, RCA may be
preferred [113]. Moreover, it has been suggested that
citrate may provide some neuroprotection by attenuating
hypoxic neuronal injury through its effects on astrocytes
and oxidative phosphorylation [114].
Conclusion: multiple organ support therapy
Critically ill patients often develop multiple organ dysfunc-
tion. New extracorporeal therapies are being designed to
provide supportive treatment beyond the classic renal
indications. In the near future, technical developments in
extracorporeal devices will lead to the creation of multiple
organ support therapies, so that comprehensive replace-
ment or at least support can be provided to multiple organs
simultaneously. New machines already include multiple
platforms in which different circuits and filters can be used
in combination to support renal, heart, liver, and lung
function. Such machines ideally will be able to automatic-
ally detect both ‘traditional’ (urea) and ‘inflammatory’
(cytokines) solutes in plasma of critically ill patients in
order to automatically (or semi-automatically) tailor the
therapy toward the ‘perfect blood purification’ system
(Figure 1). Along with technological advances, organizational
issues at the institutional level, staff training, and operator
knowledge of critical care nephrology need to be improved
in order to optimize the safe and effective use of RRT.
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